Close Menu

Breaking News

With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.

The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.

Last week, GenomeWeb's readers were most interested in announcement from Qiagen that it has partnered with Illumina to develop NGS-based IVD kits.

The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.

Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.

Thousands of parent-child exomes helped researchers identify apparently causative mobile element insertions in a handful of children with developmental disorders.

The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.

The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.

The companies are collaborating to return actionable genetic information to all participants of the Project Baseline Health Study.

Researchers analyzed data from 23andMe and the UK Biobank to find that errors of recombination, like uniparental disomy, can be present among healthy individuals.

The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.

A new study in Science used allele-specific expression data to find candidate genes that may have contributed to mendelian muscle disease in patients.

Using ancient DNA profiling, isotope analyses, and archeological clues, investigators saw high-status, male-centered families, along with more modest graves for unrelated individuals.

The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.

Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.

The grant will co-fund a year-long project to validate Biofidelity's chemistry to detect mutations used to guide non-small-cell lung cancer treatment.

According to the DOJ, the company also accepted a 25-year ban on participating in any federal healthcare program.

Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.

The researchers molecularly characterized cells found in cirrhotic tissue that express genes involved in pro-fibrogenic pathways that could be targeted by drugs.

The company aims to repurpose drugs by translating the mechanisms that allow hibernating animals to withstand the stresses of extended sleep.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.